New drug shows promise for Hard-to-Treat breast cancers in Real-World study
NCT ID NCT07358182
First seen Jan 23, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This study is tracking 300 people with HER2-positive or HER2-low breast cancer who are receiving trastuzumab-rezetecan as part of their routine care. Researchers are monitoring side effects and how well the drug works in real-world conditions, not in a strict lab setting. The goal is to see if this treatment is safe and effective for everyday patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab-rezetecan
What this could lead to
If successful, this could show that trastuzumab-rezetecan is a safe and effective treatment option for people with HER2-positive or HER2-low breast cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage evidence, and side effects or limited effectiveness could emerge.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.